Ars Pharmaceuticals Inc (SPRY)
EBITDA Margin
-176.61%
Quarterly · Period ending:
SPRY EBITDA Margin
Latest reported-176.61%period ending
Latest reported-176.61%period ending
SPRY Quarterly EBITDA Margin (0.00% → -176.61%)
Quarterly ebitda margin
High-resolution chart · PNG
SPRY ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| -176.6118% | |
| -254.7507% | |
| -145.9287% | |
| -150.1461% | |
| -283.7946% | |
| -422.1748% | |
| 58.1883% | |
| -923.9362% | |
| -2,499.6% | |
| 0% | |
| 0% | |
| 0% | |
| -173,500% | |
| -74,705% | |
| 0% | |
| -3,479.3651% | |
| -1,278.4483% | |
| -1,085.9729% | |
| -624.6684% | |
| -997.9167% | |
| -196.7093% | |
| -188.0919% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |